{
  "ticker": "SUPN",
  "company_name": "Supernus Pharmaceuticals, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT01994109",
      "title": "Efficacy and Safety Study of MYOBLOC\u00ae Followed by Open-Label Multiple-Treatment With MYOBLOC\u00ae in the Treatment of Troublesome Sialorrhea in Adult Subjects",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Sialorrhea",
      "start_date": "2013-11",
      "completion_date": "2017-01",
      "enrollment": 0,
      "sponsor": "Supernus Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT05097079",
      "title": "Efficacy and Safety Study of MYOBLOC in the Treatment of Sialorrhea in Pediatric Subjects",
      "status": "WITHDRAWN",
      "phase": "PHASE3",
      "condition": "Sialorrhea",
      "start_date": "2021-11",
      "completion_date": "2023-05",
      "enrollment": 0,
      "sponsor": "Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC"
    },
    {
      "nct_id": "NCT03597503",
      "title": "Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD Treatment",
      "status": "TERMINATED",
      "phase": "PHASE3",
      "condition": "Attention Deficit Hyperactivity Disorder",
      "start_date": "2018-07-31",
      "completion_date": "2020-01-22",
      "enrollment": 0,
      "sponsor": "Supernus Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT00918047",
      "title": "Study of PK and Safety of OXC (Oxcarbazepine) XR (Extended Release) as Adjunctive Therapy in Pediatric Epilepsy Patients",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Epilepsies, Partial",
      "start_date": "2009-06",
      "completion_date": "2010-11",
      "enrollment": 0,
      "sponsor": "Supernus Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT04099667",
      "title": "Efficacy and Safety Study of MYOBLOC\u00ae in the Treatment of Adult Lower Limb Spasticity",
      "status": "UNKNOWN",
      "phase": "PHASE2, PHASE3",
      "condition": "Spasticity",
      "start_date": "2019-12-17",
      "completion_date": "2024-07",
      "enrollment": 0,
      "sponsor": "Supernus Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT02549573",
      "title": "Outpatient Physical Therapy Intervention in Subjects With Parkinson's Disease Currently Using APOKYN\u00ae",
      "status": "TERMINATED",
      "phase": "PHASE4",
      "condition": "Parkinson's Disease, Motor Symptoms",
      "start_date": "2016-01",
      "completion_date": "2016-12",
      "enrollment": 0,
      "sponsor": "MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals"
    },
    {
      "nct_id": "NCT03280342",
      "title": "Cognitive Effects of Immediate Release Topiramate vs Extended Release Topiramate in Patients With Migraine",
      "status": "WITHDRAWN",
      "phase": "PHASE2",
      "condition": "Migraine, Headache",
      "start_date": "2017-10-30",
      "completion_date": "2018-09-13",
      "enrollment": 0,
      "sponsor": "University of Minnesota"
    },
    {
      "nct_id": "NCT03247517",
      "title": "Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Adolescents With ADHD",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "ADHD",
      "start_date": "2017-11-02",
      "completion_date": "2018-10-17",
      "enrollment": 0,
      "sponsor": "Supernus Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT02052739",
      "title": "Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus",
      "status": "COMPLETED",
      "phase": "PHASE1, PHASE2",
      "condition": "Super-refractory Status Epilepticus",
      "start_date": "2014-03-21",
      "completion_date": "2015-05-03",
      "enrollment": 0,
      "sponsor": "Supernus Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT03247556",
      "title": "Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Adolescents With ADHD",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "ADHD",
      "start_date": "2017-11-20",
      "completion_date": "2019-02-14",
      "enrollment": 0,
      "sponsor": "Supernus Pharmaceuticals, Inc."
    }
  ],
  "summary": {
    "total_trials": 50,
    "by_phase": {
      "PHASE3": 15,
      "PHASE1": 7,
      "PHASE2, PHASE3": 2,
      "PHASE4": 6,
      "PHASE2": 13,
      "PHASE1, PHASE2": 2,
      "": 4,
      "EARLY_PHASE1": 1
    },
    "by_status": {
      "COMPLETED": 32,
      "WITHDRAWN": 3,
      "TERMINATED": 5,
      "UNKNOWN": 3,
      "NOT_YET_RECRUITING": 2,
      "ACTIVE_NOT_RECRUITING": 2,
      "RECRUITING": 1,
      "APPROVED_FOR_MARKETING": 2
    },
    "active_trials": 3,
    "completed_trials": 32,
    "conditions": [
      "ADHD",
      "Alzheimer Disease, Cognitive Dysfunction, Mild Dementia",
      "Attention Deficit Disorder With Hyperactivity, Conduct Disorder",
      "Attention Deficit Hyperactivity Disorder",
      "Attention Deficit Hyperactivity Disorder (ADHD)",
      "Attention Deficit Hyperactivity Disorder (ADHD), Impulsive Aggression",
      "Attention-Deficit/Hyperactivity Disorder",
      "Attention-Deficit/Hyperactivity Disorder (ADHD)",
      "Epilepsies, Partial",
      "Epilepsy",
      "Epilepsy, Seizures, Epileptic",
      "Focal Impaired Awareness Seizures",
      "Healthy Lactating Women",
      "Healthy Volunteer",
      "Healthy Volunteers",
      "Huntington Disease",
      "Huntington's Disease",
      "Idiopathic Parkinson Disease",
      "Idiopathic Parkinson's Disease",
      "Impulsive Aggression Comorbid With ADHD",
      "Major Depressive Disorder (MDD)",
      "Migraine Disorders, Headache Disorders",
      "Migraine, Headache",
      "Mild Cognitive Impairment, Mild Dementia, Alzheimer's Disease",
      "Parkinson Disease, Cognitive Dysfunction",
      "Parkinson's Disease, Motor Symptoms",
      "Parkinson's Disease, Motor Symptoms, Akinesia, Hypomobility, Delayed Levodopa Onset",
      "Postpartum Depression",
      "Radiation Encephalopathy",
      "Sialorrhea",
      "Spasticity",
      "Spasticity, Cerebrovascular Accident, Multiple Sclerosis, Traumatic Brain Injury, Cervical Spinal Cord Injury, Cerebral Palsy",
      "Super-Refractory Status Epilepticus",
      "Super-refractory Status Epilepticus",
      "Tinnitus"
    ],
    "lead_stage": "commercial"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:22:10.605104",
    "search_query": "Supernus Pharmaceuticals, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Supernus+Pharmaceuticals,+Inc."
  }
}